Circular RNA: A novel type of biomarker for glioma (Review)

Sun, Wei; Zhou, Huandi; Han, Xuetao; Hou, Liubing; Xue, Xiaoying

doi:10.3892/mmr.2021.12240

Cited by 11 publications

(7 citation statements)

References 125 publications

(166 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A growing number of studies have implicated circRNAs in a number of biological processes in gliomas, including cell proliferation, metastasis, angiogenesis and oncogenesis ( 131 ). For instance, circXRCC5 was upregulated in glioma tissues and cell lines, and correlated with the poor prognosis of glioma patients ( 132 ).…”

Section: Discussion With Biomarkersmentioning

confidence: 99%

Latest updates on cellular and molecular biomarkers of gliomas

et al. 2022

View full text Add to dashboard Cite

Gliomas are the most common central nervous system malignancies, compromising almost 80% of all brain tumors and is associated with significant mortality. The classification of gliomas has shifted from basic histological perspective to one that is based on molecular biomarkers. Treatment of this type of tumors consists currently of surgery, chemotherapy and radiation therapy. During the past years, there was a limited development of effective glioma diagnostics and therapeutics due to multiple factors including the presence of blood-brain barrier and the heterogeneity of this type of tumors. Currently, it is necessary to highlight the advantage of molecular diagnosis of gliomas to develop patient targeted therapies based on multiple oncogenic pathway. In this review, we will evaluate the development of cellular and molecular biomarkers for the diagnosis of gliomas and the impact of these diagnostic tools for better tailored and targeted therapies.

show abstract

Section: Discussion With Biomarkersmentioning

confidence: 99%

Latest updates on cellular and molecular biomarkers of gliomas

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In the past 10 years, the variant in epigenesis modulator genes has been discovered to be crucial driving factor of the glioma subgroups with different clinic characteristics [ 24 , 25 ]. More and more potential regulators display the potential to be used as novel diagnostic and prognostic biomarkers for glioma [ 26 – 28 ]. Among them, the dysregulated genes with positive regulatory functions in the tumor growth and metastasis were the most hopeful biomarkers [ 29 , 30 ].…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological and Prognostic Significance of ABCC3 in Human Glioma

Fang

Huang

Cheng

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

Glioma is the most common malignant primary brain tumor with an inferior survival period and unsatisfactory prognoses. Identification of novel biomarkers is important for the improvements of clinical outcomes of glioma patients. In recent years, more and more biomarkers were identified in many types of tumors. However, the sensitive markers for diagnoses and prognoses of patients with glioma remained unknown. In the present research, our team intended to explore the expression and clinical significance of ABCC3 in glioma patients. Sequential data filtration (survival analyses, independent prognosis analyses, ROC curve analyses, and clinical association analyses) was completed, which gave rise to the determination of the relationship between glioma and the ABCC3 gene. Clinical assays on the foundation of CGGA and TCGA datasets unveiled that ABCC3 expression was distinctly upregulated in glioma and predicted a shorter overall survival. In the multivariable Cox analysis, our team discovered that the expression of ABCC3 was an independent prognosis marker for both 5-year OS (HR = 1.118, 95% CI: 1.052–1.188; P < 0.001 ). Moreover, our team also studied the association between ABCC3 expression and clinical features of glioma patients, finding that differential expression of ABCC3 was remarkably related to age, 1p19q codeletion, PRS type, chemo status, grade, IDH mutation state, and histology. Overall, our findings suggested ABCC3 might be a novel prognosis marker in glioma.

show abstract

“…Unlike traditional linear RNAs, the 3′ and 5′ ends of circRNAs are covalently connected. Therefore, circRNAs form covalently closed loop structures that resist cleavage by ribonucleases and display stronger stability, conservation and tissue/cell specificity ( 141 ). Due to these characteristics, circRNAs, as molecular targets for the malignant progression of gliomas, have demonstrated great potential in the regulation of tumourigenesis, tumour proliferation, tumour invasion and prognosis.…”

Section: Circrnas and Drug Resistance Of Gliomasmentioning

confidence: 99%

NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review)

et al. 2022

View full text Add to dashboard Cite

As the most common primary tumour of the central nervous system, gliomas have a high recurrence rate after surgical resection and are resistant to chemotherapy, particularly high-grade gliomas dominated by glioblastoma multiforme (GBM). The prognosis of GBM remains poor despite improvements in treatment modalities, posing a serious threat to human health. At present, although drugs such as temozolomide, cisplatin and bevacizumab, are effective in improving the overall survival of patients with GBM, most patients eventually develop drug resistance, leading to poor clinical prognosis. The development of multidrug resistance has therefore become a major obstacle to improving the effectiveness of chemotherapy for GBM. The ability to fully understand the underlying mechanisms of chemotherapy resistance and to develop novel therapeutic targets to overcome resistance is critical to improving the prognosis of patients with GBM. Of note, growing evidence indicates that a large number of abnormally expressed noncoding RNAs (ncRNAs) have a central role in glioma chemoresistance and may target various mechanisms to modulate chemosensitivity. In the present review, the roles and molecular mechanisms of ncRNAs in glioma drug resistance were systematically summarized, the potential of ncRNAs as drug resistance markers and novel therapeutic targets of glioma were discussed and prospects for glioma treatment were outlined. ncRNAs are a research direction for tumor drug resistance mechanisms and targeted therapies, which not only provides novel perspectives for reversing glioma drug resistance but may also promote the development of precision medicine for clinical diagnosis and treatment.

show abstract

Circular RNA: A novel type of biomarker for glioma (Review)

Cited by 11 publications

References 125 publications

Latest updates on cellular and molecular biomarkers of gliomas

Latest updates on cellular and molecular biomarkers of gliomas

Clinicopathological and Prognostic Significance of ABCC3 in Human Glioma

NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review)

Contact Info

Product

Resources

About